BOPPY-based novel fluorescent dopamine D2 and D3 receptor ligands

被引：9
|
作者：
Elek, Milica [1 ]
Dubiel, Mariam [1 ]
Mayer, Laura [2 ]
Zivkovic, Aleksandra [1 ]
Mueller, Thomas J. J. [2 ]
Stark, Holger [1 ]
机构：
[1] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut & Med Chem, Univ Str 1, D-40225 Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Inst Organ Chem, Univ Str 1, D-40225 Dusseldorf, Germany
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2022年 / 59卷
关键词：
Dopamine; BOPPY; D2R; D3R; Fluorescence; Ligands; HIGHLY FLUORESCENT; HIGH-AFFINITY; BODIPY DYES; D3; SCHIZOPHRENIA; BIOLOGY; BINDING; PROBES; TARGET;
D O I：
10.1016/j.bmcl.2022.128573
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Dopamine is one of the crucial neurotransmitters in the human brain. Its out-of-range concentration can lead to various neurological diseases with special interest for dopamine D-2 and D-3 receptor subtypes. Although BODIPY is a highly versatile structural moiety for fluorescence labeling, we have looked out for structurally related pyridine-based moieties. We used BOPPY labelling of well-described D2R/D3R pharmacophores to obtain ligands with moderate to low nanomolar binding affinities as well as low to excellent quantum yields for bright fluorescence ligands. To best of our knowledge, this is the first report on the application of BOPPY fluorophores to GPCR ligands. This approach offers a general applicable way for fluorescence labelling via primary aliphatic amine elements.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
    Osugo, Martin
    Wall, Matthew B.
    Selvaggi, Pierluigi
    Zahid, Uzma
    Finelli, Valeria
    Chapman, George E.
    Whitehurst, Thomas
    Onwordi, Ellis Chika
    Statton, Ben
    Mccutcheon, Robert A.
    Murray, Robin M.
    Marques, Tiago Reis
    Mehta, Mitul A.
    Howes, Oliver D.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [22] Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy
    Landvogt, Christian
    Buchholz, Hans-Georg
    Bernedo, Viviane
    Schreckenberger, Mathias
    Werhahn, Konrad J.
    EPILEPSIA, 2010, 51 (09) : 1699 - 1706
  • [23] Blonanserin, an Antipsychotic and Dopamine D2/D3 Receptor Antagonist, and Ameliorated Alcohol Dependence
    Takaki, Manabu
    Ujike, Hiroshi
    CLINICAL NEUROPHARMACOLOGY, 2013, 36 (02) : 68 - 69
  • [24] Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients
    Rodrigo A. Bressan
    Kjell Erlandsson
    Edgar P. Spencer
    Peter J. Ell
    Lyn S. Pilowsky
    Psychopharmacology, 2004, 175 : 367 - 373
  • [25] Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning
    Lumme, Ville
    Aalto, Sargo
    Ilonen, Tuula
    Nagren, Kjell
    Hietala, Jarmo
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2007, 156 (01) : 69 - 74
  • [26] Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats
    Breuer, Megan E.
    Groenink, Lucianne
    Oosting, Ronald S.
    Buerger, Erich
    Korte, Michiel
    Ferger, Boris
    Olivier, Berend
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 616 (1-3) : 134 - 140
  • [27] The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis
    Cui, Yin
    Prabhu, Vishwanath
    Thong Ba Nguyen
    Yadav, Binod Kumar
    Chung, Young-Chul
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (11) : 26677 - 26686
  • [28] Isoxazolylpyrrolidinylpiperazine Ligands, a New Class for Dopamine D3 and D4 Receptor Antagonists
    Oh, Yoo Na
    Kwak, Jumyung
    Koh, Hun Yeong
    Jung, Sun Ho
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2012, 33 (12) : 4227 - 4230
  • [29] Evaluation of Substituted N-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands
    Lee, Boeun
    Taylor, Michelle
    Griffin, Suzy A.
    McInnis, Tamara
    Sumien, Nathalie
    Mach, Robert H.
    Luedtke, Robert R.
    MOLECULES, 2021, 26 (11):
  • [30] Amphetamine decreases behavioral inhibition by stimulation of dopamine D2, but not D3, receptors
    van Gaalen, Marcel M.
    Unger, Liliane
    Jongen-Relo, Ana-Lucia
    Schoemaker, Hans
    Gross, Gerhard
    BEHAVIOURAL PHARMACOLOGY, 2009, 20 (5-6): : 484 - 491
12345